Collaborations

Collaborations and partnerships are an essential part of NOXXON's business strategy and we are open to discussing partnering opportunities either relating to our proprietary programs in clinical development or our Spiegelmer* technology.

We are actively collaborating with international pharmaceutical leaders, academic investigators worldwide and other research organizations to advance NOXXON’s portfolio.
The list below contains some of NOXXON's scientific advisors and collaborators.

Merck & Co. / MSD

Metastatic solid tumors that do not respond to checkpoint inhibitors:
NOXXON and Merck & Co., Inc./MSD announced a collaboration on Dec 15, 2016 under which the two companies will collaborate in a phase 1/2 clinical trial of NOXXON’s anti-CXCL12 agent, NOX-A12, and MSD’s anti-PD-1 inhibitor, Keytruda^® (pembrolizumab), in a two-part, open-label phase 1/2 study is to evaluate pharmacodynamic effects and safety of NOX-A12 as a monotherapy in addition to safety and efficacy of NOX-A12 in combination with Keytruda^® in patients with metastatic colorectal and pancreatic cancer.

The clinical trial and thus the collaboration were completed in H1 2021.

National Center for Tumor Diseases (NCT)

NOXXON collaborated with Prof. Dr. Dirk Jäger, and Dr. Niels Halama at the National Center for Tumor Diseases in Heidelberg, Germany, one of the leading centers for cancer research and treatment, to conduct their completed clinical trial in metastatic colorectal and pancreatic cancer.

At NOXXON we believe in the value of collaboration. We are seeking partners who share our vision to create impactful therapies and bring our innovative technology to market. For more information on partnering or collaborating with NOXXON please contact:

Business Development at This email address is being protected from spambots. You need JavaScript enabled to view it.